E. Schacht

No ORCID on file · 4 papers in corpus
nonrandomized-trial 2003
Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy
Maturitas ·doi:10.1016/j.maturitas.2003.07.002

OBJECTIVE: To evaluate the pharmacodynamic effects of a novel intrauterine drug delivery system, FibroPlant-levonorgestrel (LNG), on the endometrium in 24 postmenopausal women using estrogen substitution therapy (EST) to suppress climacteri…

nonrandomized-trial 2001
Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study
·doi:10.1080/713604208

AbstractObjective To evaluate the effect on menstrual blood loss of a novel 'frameless' intrauterine drug delivery system, the FibroPlant™ levonorgestrel intrauterine system (IUS), releasing 14 μg of levonorgestrel/day. An ancillary objecti…

nonrandomized-trial 2001
Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study
·doi:10.1080/713604262

Objectives: To evaluate the effect on menstrual pain in women with primary and secondary dysmenorrhea of a novel 'frameless' intrauterine drug delivery system (IUS), FibroPlant-levonorgestrel (LNG) (Contrel Research, Belgium), releasing 14 …

nonrandomized-trial 2001
Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception ·doi:10.1080/ejc.6.4.192.198

OBJECTIVES: To evaluate the effect on menstrual pain in women with primary and secondary dysmenorrhea of a novel 'frameless' intrauterine drug delivery system (IUS), FibroPlant-levonorgestrel (LNG) (Contrel Research, Belgium), releasing 14 …